Blog
Here's How Intrexon Might Prove Me Wrong
I've been quick to point out when marketing hype doesn't match up with what's realistically possible from a technical standpoint. Unfortunately, in my opinion, there have been many such instances in
Down 9.8%: Is Masimo Corporation Stock a Contrarian Buy?
Masimo Corporation (NASDAQ: MASI), a mid-cap medical technology company, reported stronger-than-expected second-quarter results after the bell Wednesday, but investors still decided to hit the exits
Soaring Sales Lift MasTec to New Records
Investors have waited to see whether anticipated increases in infrastructure spending would lift stocks of companies in the construction industry. Yet MasTec (NYSE: MTZ) decided not to wait for
Cloud Networking Strength Lifts Arista Skyward
Data centers have become increasingly important for companies to be able to collect and analyze the information they have about their businesses. Arista Networks (NYSE: ANET) has gone up against some
This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation
Few industries in the U.S. are growing at a quicker pace than legal marijuana. According to a fairly recent report from Marijuana Business Daily, entitled "Marijuana Business Factbook 2017," legal pot
Better Buy: Franco-Nevada Corporation vs. Wheaton Precious Metals
Gold and silver streaming companies Franco Nevada Corporation (NYSE: FNV) and Wheaton Precious Metals (NYSE: WPM) have very similar business models. Where they differ most is in their dividend
A Close Look at Kinder Morgan's Massive Dividend Potential
If you are a dividend investor, oil and gas midstream giant Kinder Morgan's (NYSE: KMI) 2.5% yield might not pop up on your radar screen. But over the next couple of years that's likely to change
Mobile Games Drive Massive Quarter For Activision Blizzard, Inc.
A slow quarter of new releases didn't slow down Activision Blizzard, Inc. (NASDAQ: ATVI) in the second quarter. The company posted much better than expected second quarter results, driven by continued
Why Chipotle's Earnings Beat Doesn't Matter
Chipotle Mexican Grill (NYSE: CMG) shares initially spiked after the company's second quarter earnings call, as the company reported $2.32 in earnings per share, beating analysts' expectations by
Why Sarepta Therapeutics Stock Gained 10.7% in July
Sarepta Therapeutics (NASDAQ: SRPT), a biotech developing novel treatments for rare disorders, saw its shares rise by a healthy 10.7% last month, according to S&P Global Market Intelligence. The
This Bank Is About to Raise Its Dividend Nearly 30%
How does a nearly 30% dividend raise sound?It was undoubtedly music to the ears of Alabama-based Regions Financial (NYSE: RF) shareholders when they heard their bank was making such a hefty increase
Better Buy: Microsoft Corporation vs. International Business Machine Corp.
Most non-investing folks would have a hard time telling you exactly how IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT) make their money. The former used to make huge computers, and the latter makes
4 Questions to Ask About Your New Employer's 401k
When you start a new job, there's a lot to learn -- and not just about how to do the job you've been hired for. Understanding your employee benefits is crucial, and one of the most significant
The Simple Way to Find Your Retirement Number
There's no magical, one-size-fits-all way to calculate a retirement number. For example, I've heard many experts say that a good estimator is to multiply your current income by 25, or some similar
5 Technological Innovations That Could Change the World
Image source: Getty Images.Technology is often overhyped, but sometimes there are honest-to-goodness technological innovations that have the ability to truly change the world. Consider that artificial
Jones Lang LaSalle: Revenue Grows, Earnings to Follow
Commercial property services company Jones Lang LaSalle (NYSE: JLL) strategic growth plan remains on track, but you wouldn't think it from looking at its declining EBITDA in the first half of the
Jones Lang LaSalle: Revenue Grows, Earnings to Follow
Commercial property services company Jones Lang LaSalle (NYSE: JLL) strategic growth plan remains on track, but you wouldn't think it from looking at its declining EBITDA in the first half of the
How HCP, Inc. Makes Most of Its Money
I've written before about healthcare real estate investment trust HCP, Inc. (NYSE: HCP) and how it could be a big beneficiary of the aging U.S. population over the next few decades. While I certainly
Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?
Illumina (NASDAQ: ILMN) and Intuitive Surgical (NASDAQ: ISRG) recently reported second-quarter earnings that were better than industry watchers' forecasts. These two game-changing healthcare companies
General Communication Suffers a Sales Slump
Alaskan telecommunications company General Communication (NASDAQ: GNCMA) reported its second-quarter results after the market closed on August 2. Revenue and net income slumped, with the company
PayPal Has Plenty of Dancing Partners and Investors Should Be Thrilled
Investors have come to expect consistent growth from PayPal Holdings Inc (NASDAQ: PYPL) and it did not disappoint when it recently reported its third quarter results. Not only did the company surpass
AMC Networks Inc. Draws Strength From "Miscellaneous" Income Sources
TV content producer and distributor AMC Networks (NASDAQ: AMCX) reported second-quarter earnings early on Thursday morning. Strong domestic results outweighed weaker figures in the international
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
Cirrus Logic's Profit Surges, but Outlook Calls for Sales Drop
Audio-chip developer Cirrus Logic (NASDAQ: CRUS) reported its fiscal first-quarter results after the market closed on August 2. Solid double-digit revenue growth drove a surge in the bottom line, but
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%